Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 15/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | CNR2 | P34972 | 5/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678188 | 0.90 | SLC6A9 (0.54) | SLC6A9CYP2C9 | |
| SCHEMBL4760591 | 0.84 | SLC6A9 (0.60) | SLC6A9CYP2C9 | |
| SCHEMBL3544127 | 0.84 | SLC6A9 (0.65) | SLC6A9CYP2C9 | |
| SCHEMBL5918448 | 0.83 | SLC6A9 (0.59) | SLC6A9CYP2C9 | |
| SCHEMBL5918325 | 0.81 | SLC6A9 (0.57) | SLC6A9CYP2C9 | |
| SCHEMBL3541661 | 0.81 | SLC6A9 (0.57) | SLC6A9CYP2C9 | |
| SCHEMBL4762258 | 0.81 | SLC6A9 (0.55) | SLC6A9CYP2C9CNR2 | |
| SCHEMBL4721810 | 0.81 | SLC6A9 (0.57) | SLC6A9CYP2C9 | |
| SCHEMBL13137946 | 0.80 | SLC6A9 (0.39) | SLC6A9CYP2C9CNR2CYP2C19CYP2D6 | |
| SCHEMBL13137944 | 0.80 | SLC6A9 (0.39) | SLC6A9CYP2C9CNR2CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893566-B1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | MERCK SHARP & DOHME (GB) | 2013-02-13 | — | — | EP | claimed |
| EP-1893566-A1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | MERCK SHARP & DOHME LTD. (GB) | 2008-03-05 | — | — | EP | claimed |
| WO-2006131711-A1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | MERCK SHARP & DOHME LIMITED (GB) | 2006-12-14 | — | — | WO | claimed |
| US-20060276655-A1 | Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-12-07 | — | — | US | claimed |
| EP-1893566-B1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | MERCK SHARP & DOHME (GB) | 2013-02-13 | — | — | EP | disclosed |
| US-20110269782-A1 | USE OF NMDA ACTIVITY ENHANCERS TO TREAT HYPERSOMNIA, REDUCED WAKEFULNESS OR REDUCED VIGILANCE | MERCK, SHARP & DOHME LTD. (GB) | 2011-11-03 | — | — | US | disclosed |
| EP-2328576-A1 | USE OF NMDA ACTIVITY ENHANCERS TO TREAT HYPERSOMNIA, REDUCED WAKEFULNESS OR REDUCED VIGILANCE | Merck Sharp & Dohme Limited (GB) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010035026-A1 | USE OF NMDA ACTIVITY ENHANCERS TO TREAT HYPERSOMNIA, REDUCED WAKEFULNESS OR REDUCED VIGILANCE | MERCK SHARP & DOHME LTD (GB) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276655-A1 | Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia | GLRA1, GNMT, MGAT1 | SLC6A9 71/4885CYP2C9 1409/4885CNR2 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.